<?xml version="1.0" encoding="utf-8"?>
    <rss version="2.0">
      <channel xmlns:content="http://purl.org/rss/1.0/modules/content/">
        <title>Transplant International | New and Recent Articles</title>
        <link>https://www.frontierspartnerships.org/journals/transplant-international</link>
        <description>RSS Feed for Transplant International | New and Recent Articles</description>
        <language>en-us</language>
        <generator>Frontiers Feed Generator,version:1</generator>
        <pubDate>2026-11-10T19:11:52.13+00:00</pubDate>
        <ttl>60</ttl>
        <item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17530</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17530</link>
        <title><![CDATA[Extracorporeal life support in adult lung transplantation: a survey of Italian lung transplant]]></title>
        <pubdate>2026-11-10T00:00:00Z</pubdate>
        <category>Brief Research Report</category>
        <author>Andrea Costamagna</author><author>Domenico Pinelli</author><author>Anna Laureys</author><author>Stefania Camagni</author><author>Samuele Nicotra</author><author>Filippo Antonacci</author><author>Lorenzo P. A. Rosso</author><author>Ilaria Righi</author><author>Alessandro Bertani</author><author>Maria Scarlata</author><author>Marco Schiavon</author><author>Giorgio Cannone</author><author>Carlo Pellegrini</author><author>Antonio Sciortino</author><author>Daniele Diso</author><author>Federico Venuta</author><author>Luca Luzzi</author><author>Federico Franchi</author><author>Massimo Boffini</author><author>Matteo Marro</author><author>Andrea Dell’Amore</author><author>David Bennett</author>
        <description><![CDATA[The use of extracorporeal life support (ECLS) during lung transplantation has evolved substantially. Despite recent international consensus recommendations, significant variability persists. We conducted a national survey to describe contemporary practice patterns among Italian lung transplant centres. A 39-item, web-based survey was developed and distributed to all nine Italian lung transplant centres. The survey addressed indications for ECLS, technical aspects of extracorporeal support, anticoagulation and postoperative management. The response rate was 100%. Seven centres (77.8%) reported selective use of ECLS, whereas two (22.2%) routinely used ECLS during bilateral lung transplantations. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) was the preferred intraoperative support modality in seven centres (77.8%), while two centres (22.2%) preferred cardiopulmonary bypass. Considerable variability was observed in patient selection, anticoagulation, cannulation strategies, postoperative ECLS continuation and weaning practices. Substantial variability remains in ECLS management among Italian lung transplant centres, despite recent international consensus recommendations. These findings provide a contemporary national overview of ECLS practice and highlight the need for further patient-level and outcome-based evaluation of intraoperative ECLS strategies.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17034</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17034</link>
        <title><![CDATA[Tremor outcomes after conversion from immediate-release to LCP tacrolimus in lung transplant recipients: a randomized controlled trial]]></title>
        <pubdate>2026-11-06T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Niels L. Riemersma</author><author>Heleen Grootjans</author><author>Daan Kremer</author><author>Janna Alkema</author><author>Cheryl S. J. Everlo</author><author>A. Madelein M. van der Stouwe</author><author>Willie N. Steenhuis</author><author>Erik A. M. Verschuuren</author><author>Huib A. M. Kerstjens</author><author>Stefan P. Berger</author><author>Stephan J. L. Bakker</author><author>C. Tji Gan</author>
        <description><![CDATA[Tremor is an important, dose-dependent side effect of tacrolimus in lung transplant (LTx) recipients. We assessed whether once-daily extended-release Life Cycle Pharma (LCP) tacrolimus with lower peak concentrations results in less tremor compared with twice-daily immediate-release (IR) tacrolimus. The prospective, randomized, controlled REVOLUTION trial (NCT05001074) randomized LTx recipients to either continue IR-tacrolimus or to switch to LCP-tacrolimus. Tremor was assessed with linear mixed models, objectively with the Fahn-Tolosa-Marin Tremor Rating Scale part B and subjectively with a Visual Analog Scale, at baseline and after 1 and 2 years. We included 65 LTx recipients (56.9% men; median age: 61.8 [45.0–66.6] years), with a median of 4.9 [2.1–8.1] years having passed since their transplantation. Baseline tremor severity did not differ significantly between groups (objective tremor: IR: 5.5 [3.5–8.0] vs. LCP: 6.8 [5.5–8.3]; p = 0.3 and subjective tremor: IR: 10.0 [5.0–30.0] vs. LCP: 20.0 [10.0–30.0], p = 0.1). Tremor severity remained similar between groups over time after adjusting for age, time since transplantation, tacrolimus trough levels, and kidney function. Higher age and higher tacrolimus trough levels were associated with greater objective tremor severity (β = 0.22, p = 0.001 and β = 0.21, p = 0.036, respectively). This is, to our knowledge, the first randomized clinical trial in lung transplant recipients to evaluate the effect of conversion from IR to LCP tacrolimus on tremor severity showing no effect.Clinical Trial RegistrationClinicalTrials.gov, identifier NCT05001074.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17933</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17933</link>
        <title><![CDATA[6th ELPAT congress: ethical, legal and psychosocial aspects of transplantation: new technologies – evolving humanities]]></title>
        <pubdate>2026-11-06T00:00:00Z</pubdate>
        <category>Special Issue Editorial</category>
        <author>Christina Papachristou</author><author>Frederike Ambagtsheer</author><author>Greg Moorlock</author><author>Adnan Sharif</author><author>David Shaw</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16897</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16897</link>
        <title><![CDATA[A chimeric bladder tumor in a renal transplant recipient: the oncogenic convergence of JC virus and PIK3CA mutation]]></title>
        <pubdate>2026-11-05T00:00:00Z</pubdate>
        <category>Letter to the Editor</category>
        <author>G. Ietto</author><author>D. Dalla Gasperina</author><author>M. Gritti</author><author>P. Brani</author><author>S. La Rosa</author><author>D. Furlan</author><author>D. Inversini</author><author>G. Balzano</author><author>G. Carcano</author><author>G. Pettinato</author><author>A. Baj</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17469</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17469</link>
        <title><![CDATA[Recurrence of immunoglobulin A nephropathy after kidney transplantation: a therapeutic gap in the era of targeted therapies]]></title>
        <pubdate>2026-11-04T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Luis Sanchez-Russo</author><author>George Vasquez-Rios</author><author>Leonardo V. Riella</author><author>Paolo Cravedi</author>
        <description><![CDATA[Immunoglobulin A nephropathy (IgAN) frequently recurs after kidney transplantation and remains an underrecognized cause of allograft loss. Although targeted-release budesonide, B-cell modulators, and complement inhibitors have transformed native IgAN treatment, transplant recipients were excluded from trials, leaving management based largely on case reports, small series, and registry data. Reported recurrence rates range from 10% to 30% at 10–15 years after transplant, depending on biopsy practices and diagnostic criteria. Younger age, preemptive transplantation, and rapid progression to end-stage kidney disease are the most consistent risk factors. Two large registries suggested that maintenance corticosteroids reduce recurrence, but this association was not confirmed in propensity-matched or multicenter studies, and induction immunosuppression was not adequately accounted for. Recurrence significantly worsens graft survival, with hazard ratios for graft loss ranging from 2 to nearly 4. Mechanistically, IgAN is increasingly viewed as a disorder of B-cell and plasma-cell biology driven by the B-cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) axis, which may explain why T-cell-focused immunosuppression to prevent rejection fails to prevent recurrence. Early experience with B-cell-, plasma-cell-, and complement-targeted therapies after transplantation is encouraging but limited. Progress will require harmonized registries, validated biomarkers, industry collaboration, and dedicated randomized trials in transplant recipients.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17296</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17296</link>
        <title><![CDATA[Association of pre-transplant CT-derived perirenal fat measurements with post-transplant diabetes mellitus after kidney transplantation]]></title>
        <pubdate>2026-11-02T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>William J. Butak</author><author>Jacob Matthews</author><author>Chase Caswell</author><author>Sarah E. Miller</author><author>Jessica Chan</author><author>Badi Rawashdeh</author><author>Matthew Cooper</author><author>Ty Blink Dunn</author><author>Emre Arpali</author>
        <description><![CDATA[Post-transplant diabetes mellitus (PTDM) is a common metabolic complication after kidney transplantation with important implications for patient and graft outcomes. We evaluated the association between pre-transplant computed tomography (CT)-derived adiposity measurements and the development of PTDM. We retrospectively studied adult kidney transplant recipients who underwent pre-transplant abdominal CT imaging. CT-derived adiposity measurements were obtained at standardized anatomical locations. Multivariable logistic regression models were constructed for each imaging parameter after adjustment for age, sex, and body mass index. Model discrimination was assessed using receiver operating characteristic analysis. Among all CT-derived adiposity measurements, right anterior perirenal fat thickness demonstrated the strongest independent association with PTDM (adjusted OR 1.07, 95% CI 1.03–1.12; P = 0.001). Right maximum perirenal fat thickness (adjusted OR 1.04, 95% CI 1.00–1.08; P = 0.028) and anterior subcutaneous fat thickness (adjusted OR 1.05, 95% CI 1.02–1.09; P = 0.005) were also independently associated with PTDM, whereas other CT-derived adiposity measurements were not. Pre-transplant right anterior perirenal fat thickness is independently associated with PTDM after kidney transplantation and improves prediction beyond conventional clinical risk factors. This simple CT-derived measurement may enhance pre-transplant metabolic risk assessment and warrants validation in prospective multicenter studies.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17466</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17466</link>
        <title><![CDATA[Robotic-assisted living donor-initiated domino liver transplantation: a window of opportunity for transplant oncology]]></title>
        <pubdate>2026-11-02T00:00:00Z</pubdate>
        <category>Letter to the Editor</category>
        <author>Rani Kassir</author><author>Xavier Muller</author><author>Kayvan Mohkam</author><author>Teresa Antonini</author><author>Barbara Rohmer</author><author>Rémi Dubois</author><author>Jean-Yves Mabrut</author><author>Guillaume Rossignol</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17558</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17558</link>
        <title><![CDATA[RSV-specific humoral and cellular immune responses in kidney transplant recipients]]></title>
        <pubdate>2026-10-30T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Britte G. Lenderink</author><author>Laura L. A. van Dijk</author><author>Marjolein Dieterich</author><author>Marcia M. L. Kho</author><author>Sebastiaan Heidt</author><author>Rory D. de Vries</author>
        <description><![CDATA[Induction of virus-specific immune responses in kidney transplant recipients (KTR) by vaccination is challenging. However, it is not well-described whether pre-existing immunity against respiratory viruses initially encountered before transplantation, like respiratory syncytial virus (RSV), is maintained. Therefore, we assessed RSV-specific humoral and cellular immune responses in KTR and controls at two timepoints during the COVID-19 pandemic. Binding and neutralizing antibodies were determined in serum samples from 64 KTR and 37 controls. Cellular immune responses were measured in a cohort subset (15 KTR, 14 controls) by stimulation of peripheral blood mononuclear cells with RSV-derived peptide pools. This was followed by phenotypic analysis using an activation-induced marker assay and cytokine release assay. RSV-specific binding IgG and neutralizing antibody titers were comparable between KTR and controls and stable over time. While total lymphocyte levels were significantly lower in KTR, relative frequencies of RSV-specific CD4+ and CD8+ memory T cells were comparable between groups. Unsupervised hierarchical clustering distinguished three cytokine production profiles with divergent RSV-specific immune responses, but KTR and controls were equally distributed throughout. Thus, KTR have comparable RSV-specific humoral and cellular immune responses to controls. Our findings suggest that pre-existing respiratory virus-specific immune responses persist under immunosuppressive treatment.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17955</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17955</link>
        <title><![CDATA[The bladder’s turn: first-in-human combined bladder–kidney transplantation]]></title>
        <pubdate>2026-10-28T00:00:00Z</pubdate>
        <category>News and Views</category>
        <author>Emilien Seizilles de Mazancourt</author><author>Oriol Bestard</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17841</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17841</link>
        <title><![CDATA[Editorial: Silver linings: navigating the challenges and opportunities of organ transplantation in an Ageing population]]></title>
        <pubdate>2026-10-23T00:00:00Z</pubdate>
        <category>Special Issue Editorial</category>
        <author>Thierry Berney</author><author>Annelies de Weerd</author><author>Katja Kotsch</author><author>Simon Moosburner</author><author>Jasper Iske</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17721</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17721</link>
        <title><![CDATA[The birth of the European Liver transplant registry]]></title>
        <pubdate>2026-10-22T00:00:00Z</pubdate>
        <category>News and Views</category>
        <author>Henri Bismuth</author>
        <description><![CDATA[This personal account, written on the occasion of the fortieth anniversary of the European Liver Transplant Registry (ELTR), traces the origins of the Registry from the earliest days of liver transplantation in Europe to its present scale. Beginning with a handful of pioneering centres in the 1970s and the scepticism that surrounded the procedure, the narrative follows the events of 1983 that transformed the field, the creation of an informal registry at Paul Brousse, and its extension to a European network following a founding meeting in Hannover in October 1985. It describes the early design choices that shaped the Registry, the methodological debates that defined its core definitions, and the scientific contributions that followed, including landmark findings on patient survival and on hepatitis B recurrence after transplantation, as well as the 1993 Paris Consensus Conference on indications for liver transplantation. The account closes with the Registry’s transition to new stewardship and its present scope, spanning more than 200,000 transplants recorded across 32 countries. The history illustrates how informal, trust-based collaboration among a small number of European surgeons gave rise to one of the longest-running transplant registries in the world.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17284</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17284</link>
        <title><![CDATA[Post-transplant oncologic outcomes after locoregional downstaging before living donor liver transplantation for hepatocellular carcinoma beyond Milan criteria: a systematic review and meta-analysis of selected cohorts]]></title>
        <pubdate>2026-10-20T00:00:00Z</pubdate>
        <category>Systematic Review and Meta-Analysis</category>
        <author>Younggoun Jo</author><author>Yunchul Park</author><author>Ho-Kyun Lee</author><author>Sola Lee</author><author>Hong-Sung Jung</author><author>Soo Jin Na Choi</author><author>Hyo-Sin Kim</author>
        <description><![CDATA[Downstaging of hepatocellular carcinoma (HCC) before liver transplantation is established mainly in the deceased donor setting, and outcomes before living donor liver transplantation (LDLT) remain unclear. We searched PubMed and Embase through April 2026 for studies reporting post-transplant outcomes in patients with HCC beyond Milan criteria who were downstaged before LDLT. A pre-specified primary analysis covered locoregional therapy targeting Milan or UCSF criteria. We pooled proportions using random-effects models and reconstructed patient-level survival from Kaplan-Meier curves. Seventeen studies with 511 downstaged LDLT recipients were included. In the primary cohort, recurrence was 22.1% (95% CI 9.7–42.6) and 5-year overall survival 75.8% (61.8–85.8). Across all studies, recurrence was 25.0% (17.4–34.5), 5-year overall survival 75.0% (63.1–84.1), and downstaging success 47.5% (36.1–59.1); reconstructed 5-year overall and recurrence-free survival were 75.7% and 75.6%. These estimates describe patients who achieved downstaging—fewer than half of those who attempted it—and then reached transplant. They do not measure the benefit of downstaging itself. The evidence remains retrospective and mostly Asian, with wide variation between studies. Prospective intention-to-treat studies are needed.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17803</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17803</link>
        <title><![CDATA[When the model defines the message: methodological considerations in experimental lung warm ischemia]]></title>
        <pubdate>2026-10-16T00:00:00Z</pubdate>
        <category>Forum</category>
        <author>Jitte Jennekens</author><author>Daan Imholz</author><author>Sue Braithwaite</author><author>Linda de Heer</author><author>Arne Neyrinck</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17326</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17326</link>
        <title><![CDATA[Logistics of clinical xenotransplantation: from donor pig production to global organ distribution]]></title>
        <pubdate>2026-10-15T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Konrad Fischer</author><author>Joachim Denner</author><author>Ralf Reinhard Tönjes</author><author>Philipp Felgendreff</author><author>Axel Rahmel</author>
        <description><![CDATA[The shortage of transplantable organs remains one of the most significant unmet challenges in modern medicine. Despite advances in donor management, organ preservation, surgical techniques, and immunosuppression, organ demand continues to exceed supply worldwide. Xenotransplantation using genetically engineered porcine organs has emerged as a promising strategy to address this gap. Recent clinical pig-to-human heart and kidney transplantations have demonstrated the feasibility of clinical xenotransplantation and shifted attention from immunological barriers toward practical implementation. This review examines the logistical requirements for clinical xenotransplantation, with particular emphasis on donor herd management, biosafety, organ preservation technologies, and future distribution networks. The integration of donor production with advanced machine perfusion technologies may ultimately transform transplantation medicine from a donor-dependent emergency service into a predictable and scalable therapeutic platform.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17047</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17047</link>
        <title><![CDATA[Stereotactic body radiation therapy and radioembolization as bridging strategies to liver transplantation: a retrospective real-world analysis]]></title>
        <pubdate>2026-10-14T00:00:00Z</pubdate>
        <category>Letter to the Editor</category>
        <author>Nicola Colucci</author><author>Mitchell A. Webb</author><author>Muhammad Uzair Khalid</author><author>Anastasios D. Giannou</author><author>Yuwei Yang</author><author>Tyler D. Yan</author><author>Lok In Josephine Ma</author><author>Ravjot Dhatt</author><author>Stéphanie Chartier-Plante</author><author>Peter T. W. Kim</author><author>Graziano Oldani</author><author>Maja Segedi</author><author>Roy M. K. Ma</author><author>Stephen G. F. Ho</author><author>Emma M. Dunne</author><author>Michael S. Bleszynski</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17130</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17130</link>
        <title><![CDATA[Urinary CXCL10 for detection of rejection and infection at 1-year posttransplant]]></title>
        <pubdate>2026-10-12T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Alain M. Häseli</author><author>Karoline Leuzinger</author><author>Matthias Diebold</author><author>Caroline Wehmeier</author><author>Joëlle Handschin</author><author>Patrizia Amico</author><author>Michael Dickenmann</author><author>Pietro E. Cippà</author><author>Helmut Hopfer</author><author>Patricia Hirt-Minkowski</author><author>Stefan Schaub</author>
        <description><![CDATA[Urinary CXCL10 chemokine levels correlate with inflammatory processes in the reno-urinary tract after kidney transplantation. The aim of this study was to investigate the diagnostic characteristics of urinary CXCL10/creatinine ratio to detect major inflammatory processes (i.e., subclinical rejection, relevant JC/BK polyomavirus DNAuria, or significant leukocyturia) in 405 stable renal allograft recipients with surveillance biopsies at 1 year posttransplant. Urinary CXCL10/creatinine had a significantly higher area under the curve (AUC) than serum creatinine or proteinuria (0.786 vs. 0.499 vs. 0.636; both p < 0.0001) for detection of inflammatory processes. The highest AUC was observed for the detection of BK polyomavirus DNAuria (0.936), but it was lower for detection of subclinical rejection (0.703). At an arbitrary rule-out cutoff (CXCL10/creatinine <3 ng/mmol; 59% of all patients; negative likelihood ratio 0.36), 51% of surveillance biopsies could be safely deferred, and the risk of subclinical rejection decreased from 15.8% to 5.4%. At an arbitrary rule-in cutoff (CXCL10/creatinine >10 ng/mmol; 12% of all patients; positive likelihood ratio 12.92), absence of any inflammatory pathologies was only 2%. These data support urinary CXCL10/creatinine measurements at 1-year posttransplant in stable allografts to detect inflammatory processes and guide further diagnostics. The preliminary cutoffs require external validation.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16922</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16922</link>
        <title><![CDATA[Differences in excess mortality by recipient sex after liver transplant]]></title>
        <pubdate>2026-10-12T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Lauren Tal Grinspan</author><author>Xun Zhang</author><author>Mourad Dahhou</author><author>Caner Süsal</author><author>Doehler Bernd</author><author>Anette Melk</author><author>Amanda Vinson</author><author>Bethany J. Foster</author>
        <description><![CDATA[Identification of sex differences in mortality may prompt sex-specific management strategies. Males worldwide have higher mortality than females; therefore, we compared sex differences in excess mortality. We compared excess mortality in female versus male first liver transplant recipients, accounting for modifying effects of donor sex and recipient current age using relative survival models. Models were fitted separately in Scientific Registry of Transplant Recipients and CTS cohorts (1988–2019) and subsequently combined using two-stage individual patient data meta-analysis. We analyzed 218,429 patients. Within the first 3 months post-transplant, female recipients ≥25 years showed significantly higher excess mortality regardless of donor sex and female recipients 13–24 years had significantly higher excess mortality when the donor was male. Subsequent to the first 3 months, female recipients 0–12 years had significantly lower excess mortality regardless of donor sex; female recipients ≥25 years had lower excess mortality, though only significantly among those 25–44 years with a female donor. Females ≥25 years showed higher excess mortality than males in the immediate post-transplant period but, among those who survived, the first 3 months, excess mortality was similar by sex or lower in females than males. After the first 3 months post-transplant, female recipients 0–12 years showed lower excess mortality.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17141</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17141</link>
        <title><![CDATA[Changes in rat intestinal motility and absorption following intestinal transplantation: an experimental study]]></title>
        <pubdate>2026-10-09T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Antoine Dubois</author><author>Amélie Leenders</author><author>Gert De Hertogh</author><author>Alice Rustichelli</author><author>Caroline Boelhouwer</author><author>Tine Wylin</author><author>Veerle Heedfeld</author><author>Eliano Bonaccorsi-Riani</author><author>Jacques Pirenne</author><author>Tim Vanuytsel</author><author>Ricard Farré</author><author>Laurens J. Ceulemans</author>
        <description><![CDATA[Intestinal transplantation (ITx) is a life-saving procedure for patients with complicated intestinal failure. In the acute phase, allograft permeability increases primarily due to ischemia-reperfusion injury. However, long-term allograft physiology after transplantation remains poorly understood, particularly the impact of lost autonomous graft innervation. This study aims to evaluate post-ITx allograft motility and permeability using orally administered fluorescein-labeled dextrans (TRITC70,FITC4). Lewis-to-Lewis orthotopic ITx (n = 6, 260–300 g) were performed. Intestinal permability and motility were evaluated in recipient at baseline (2 days pre-transplant, control) and 4 weeks post-transplant (experimental), using orally administered dextrans (TRITC70 and FITC4). Total GI motility was assessed by TRITC70 fecal excretion, while intestinal and colonic permeability were evaluated using TRITC70 (transcellular route) and FITC4 (paracellular route) plasma concentrations, measured at 3 h, 6 h, 24 h. Paired data were reported as mean (±SEM) and compared using paired t-test (normal distribution)/Wilcoxon rank test (non-normal distribution). Fecal excretion of TRITC70 was 9.58 (±0.85) hours in the control group and 11.02 (±1.40) hours in the experimental group (p = 0.287). Plasma concentrations (µg/mL) of FITC4 at 3 h, 6h, and 24 h were (control vs. experimental): 0.23 (±0.08) vs. 0.72 (±0.23) (p = 0.041), 0.12 (±0.06) vs. 0.53 (±0.16) (p = 0.031), and 0.04 (±0.02) vs. 0.12 (±0.04) (p = 0.625). For TRITC70, plasma concentrations were 11.20 (±1.81) vs. 11.11 (±1.39) (p = 0.975), 20.49 (±8.87) vs. 12.60 (±1.87) (p = 0.562), and 20.82 (±7.25) vs. 5.02 (±0.82) (p = 0.094). Finally, the AUC (µgh/mL) of FITC4 and TRITC70 absorption were 2.39 (±1.1) vs. 8.84 (±2.69) (p = 0.029) and 436 (±159) vs. 197 (±25) (p = 0.195), respectively. Four weeks after ITx, we observed an increased paracellular permeability compared to pre-transplant evaluation, while overall GI motility remained unchanged. Further research is needed to better understand intestinal graft physiology.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16414</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16414</link>
        <title><![CDATA[Lower lung donor PaO2/FiO2 ratio correlates with early primary graft dysfunction, but does not impact overall survival after lung transplantation: a dual center study]]></title>
        <pubdate>2026-10-09T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Rene Novysedlak</author><author>Cedric Vanluyten</author><author>Jan Van Slambrouck</author><author>Annalisa Barbarossa</author><author>Hanne Beeckmans</author><author>Dirk Van Raemdonck</author><author>Paul De Leyn</author><author>Hans Van Veer</author><author>Lieven Depypere</author><author>Yanina Jansen</author><author>Bart M. Vanaudenaerde</author><author>Robin Vos</author><author>Ann Belmans</author><author>Andrea Zajacova</author><author>Monika Svorcova</author><author>Jaromir Vajter</author><author>Janis Tavandzis</author><author>Jiri Pozniak</author><author>Jan Simonek</author><author>Zuzana Ozaniak Strizova</author><author>Jiri Vachtenheim</author><author>Robert Lischke</author><author>Laurens J. Ceulemans</author>
        <description><![CDATA[Extended criteria donor lungs falling below the arbitrarily set PaO2/FiO2 (PFR) threshold of 300 are frequently declined despite other acceptable parameters. This two-center retrospective analysis investigates whether donor PFR is a risk factor for outcomes after lung transplantation (LuTx). A retrospective cohort analysis was conducted at University Hospitals Leuven, Belgium and Motol University Hospital, Prague, Czech Republic including adult LuTx recipients from 2010 to 2022 (Leuven) and 2018–3/2023 (Prague). Primary endpoints: primary graft dysfunction (PGD) grade 3 at 24 and 72 h and 2‐year overall survival. Secondary endpoints: incidence of ACR and CLAD-free survival. Donor PFR was measured from an arterial blood gas sample. Logistic and Cox regression analyses were employed to assess correlations, while survival was analyzed using Kaplan-Meier estimates. A total of 984 LuTx recipients were included. Median follow-up was 4 years. Recipients were predominantly male (54%), with chronic obstructive pulmonary disease being the most common indication for transplantation. Donor characteristics included median age of 51 years, and 18% of donors were DCD. Analyses identified lower donor PFR as a risk factor for PGD grade 3 at 24 h, but not at 72 h. PFR was not associated with the incidence of ACR or with 2-year overall survival after LuTx. Donor PFR does not appear to be a risk factor for development of late PGD or for adversely impacting outcomes. However, it is associated with increased risk of early PGD.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17780</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17780</link>
        <title><![CDATA[Editorial: Europeans and xenotransplantation]]></title>
        <pubdate>2026-10-07T00:00:00Z</pubdate>
        <category>Special Issue Editorial</category>
        <author>Emanuele Cozzi</author><author>David K. C. Cooper</author>
        <description></description>
      </item>
      </channel>
    </rss>